Clinical trials: ST Elevation (STEMI) Myocardial Infarction
STEMI - ST Elevation Myocardial Infarction, CAD
CorPath GRX STEMI Study
This study will evaluate the performance of the CorPath GRX System in Robotic Primary PCI (RPPCI) in the treatment of ST-elevated myocardial infarction (STEMI).
- Trial name
- TREAT GRX (NCT04459299)
- Testing
- Robotic-PCI (CorPath GRX System)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Siemens Healthineers Endovascular Robotics, Inc.
ST Elevation Myocardial Infarction
A Prospective Evaluation of Clinical Impact of Physiology Versus Optical Coherence Tomography Guided PCI in STEMI Patients Without Undergoing Primary PCI
This study of physiologically functional FFR in STEMI patients without direct PCI treatment will provide unique data on plaque progression and risk factors.
- Trial name
- NCT04996277
- Testing
- angiography, Thrombus suction, Fibrinolytic therapy
- Volunteers
- 300 people
- Sponsor
- CCRF Inc., Beijing, China
Acute Myocardial Infarction
Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction
This study will test compare the Stentys Stent with the Multi-Link Vision™ stent system (Abbott Vascular Inc.)in patients with a heart attack. It is expected that the Stentys stent is not worse than the Vision stent.
- Trial name
- APPOSITION V (NCT01732341)
- Testing
- STENTYS self-apposing stent, VISION balloon-expandable stent
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 318 people
- Sponsor
- Stentys
Coronary Artery Disease, Stable Angina
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data…
- Conditions
- Coronary Artery Disease, Stable Angina, Ischemia, Acute Coronary Syndrome
- Trial name
- NCT02871622
- Testing
- BioMatrix AlphaTM
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Biosensors Europe SA
Coronary Artery Disease
SELUTION 4 De Novo Small Vessel IDE Trial
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as…
- Trial name
- NCT05946629
- Testing
- PCI with SELUTION SLR DCB, PCI with FDA approved "-limus" DES
- Where
- 70 sites in United States, Belgium and 1 more
- Volunteers
- 960 people
- Sponsor
- M.A. Med Alliance S.A.
Coronary Artery Disease
BIOFLOW III Satellite-ELADIS Orsiro Stent System
This registry is a clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT02029092
- Where
- 14 sites in Spain
- Volunteers
- 404 people
- Sponsor
- C.E.M. Biotronik, S.A.
Myocardial Infarction, Coronary Arteriosclerosis
Randomized Clinical Trial of Adipose-Derived Stem Cells in the Treatment of Pts With ST-elevation Myocardial Infarction
The purpose of this study is to establish safety and feasibility of utilizing Adipose-Derived Stem and Regenerative Cells (ADRC's) in patients who have suffered a ST-elevation acute myocardial infarction.
- Conditions
- Myocardial Infarction, Coronary Arteriosclerosis, Cardiovascular Disease, Coronary Disease
- Trial name
- NCT00442806
- Testing
- Injection of ADRC's
- Where
- 2 sites in Netherlands, Spain
- Volunteers
- 14 people
- Sponsor
- Cytori Therapeutics
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Canada Satellite Registry
For the majority of Coronary Artery Disease (CAD), treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedural success.
- Trial name
- NCT01880242
- Where
- 2 sites in Canada
- Volunteers
- 250 people
- Sponsor
- Biotronik Canada Inc
Myocardial Infarction, Reperfusion Injury
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
This study is open to adults with ST elevation myocardial infarction (heart attack) undergoing primary percutaneous coronary intervention (PCI).
- Conditions
- Myocardial Infarction, Reperfusion Injury, AMI, STEMI (ST Elevation MI)
- Trial name
- PROTECT-MI (NCT07362446)
- Testing
- Xolatryp
- Where
- 8 sites in Australia
- Volunteers
- 300 people
- Sponsor
- Nyrada Pty Ltd
Acute Myocardial Infarction
Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction
This was a double-blind, randomized, placebo-controlled study that was designed to enroll a total of 225 participants with de novo anterior wall acute ST-segment elevation myocardial infarction (STEMI) due to a lesion of the left…
- Trial name
- AMICI (NCT01781390)
- Testing
- Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M
- Volunteers
- 106 people
- Sponsor
- Mesoblast, Inc.
Acute Myocardial Infarction (AMI)
Artificial Intelligence Scalable Solution for ST Myocardial Infarction
The ASSIST clinical study is an observational, multicenter study to assess the performance of a cloud-based and AI-powered electrocardiogram (ECG) analysis platform, named Willem™, developed to detect Acute Myocardial Infarction…
- Trial name
- ASSIST (NCT06939738)
- Where
- 5 sites in Portugal, Spain
- Volunteers
- 489 people
- Sponsor
- Idoven 1903 S.L.
Acute Myocardial Infarction, STEMI
Evaluation in STEMI Patients Using FDY-5301
To assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events in subjects with an anterior STEMI undergoing pPCI.
- Conditions
- Acute Myocardial Infarction, STEMI, Percutaneous Coronary Revascularization
- Trial name
- IOCYTE AMI-3 (NCT04837001)
- Testing
- FDY-5301
- Where
- 52 sites in United States, Canada and 4 more
- Volunteers
- 2,351 people
- Sponsor
- Faraday Pharmaceuticals, Inc.
Acute Coronary Syndrome
PiCSO in ACS Study
The purpose of this research study is to find out whether PICSO (Pressure Controlled Coronary Sinus Occlusion), given concomitant to (NSTEMI) or following (STEMI) primary PCI and stenting, can improve final infarct size and…
- Trial name
- NCT02197325
- Testing
- PICSO
- Where
- 4 sites in United Kingdom
- Volunteers
- 99 people
- Sponsor
- Miracor Medical SA
Left Ventricular Dysfunction, Coronary Artery Disease
Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function
The purpose of this study is to assess if using the Impella® CP (or Impella® 2.5) device during high-risk PCI in patients with reduced left-sided heart function will result in an improvement in symptoms, heart function and health…
- Trial name
- PROTECT IV (NCT04763200)
- Testing
- Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
- Where
- 110 sites in United States, Canada and 5 more
- Volunteers
- 1,252 people
- Sponsor
- Abiomed Inc.
Acute Myocardial Infarction, Heart Failure
Inflammation-mediated Coronary Plaque Vulnerability, Myocardial Viability and Ventricular Remodeling
VIABILITY study aims to investigate the link between systemic inflammation, pancoronary plaque vulnerability (referring to the plaque vulnerability within the entire coronary tree), myocardial viability and ventricular remodeling…
- Trial name
- VIABILITY (NCT03830944)
- Testing
- Blood sampling, transthoracic echocardiography, Late Gadolinium-Enhancement Cardiac Magnetic Resonance
- Where
- Romania
- Volunteers
- 150 people
- Sponsor
- Cardio Med Medical Center
Acute Myocardial Infarction With ST Elevation
Analysis of the Efficacy of Cardiac Ischemic Postconditioning With New Clinical End-points Using Novel Biomarkers
The aim of the present study was to investigate the efficacy of ischemic postconditioning in acute myocardial infarction patients. The safety of patients enrolled in the study was ensured during the entire study.
- Trial name
- NCT04824716
- Testing
- Postconditioning, Percutaneous coronary intervention
- Where
- 3 sites in Hungary
- Volunteers
- 100 people
- Sponsor
- Peter Ferdinandy
Non STEMI, Unstable Angina
Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography
The objective of this study is to evaluate CMX-2043 for prevention of renal and cardiac injury associated with coronary angiography in patients with acute coronary syndrome (ACS), but excluding ST-elevation myocardial infarction…
- Trial name
- CARIN (NCT02103959)
- Testing
- CMX-2043
- Volunteers
- 361 people
- Sponsor
- Ischemix, LLC
Acute Coronary Syndrome
Long-term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Russia
EPICOR-RUS is a multi-centre, observational, prospective, longitudinal cohort study which will include patients, in a real-life setting, who are hospitalized for acute coronary syndrome (ACS) within 24 hours of symptom onset and…
- Trial name
- EPICOR-RUS (NCT01373957)
- Where
- 19 sites in Russia
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Myocardial Infarction (MI), Acute Coronary Syndromes (ACS)
A Clinical Trial to Demonstrate the Efficacy of Cangrelor
The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.
- Trial name
- PCI (NCT00305162)
- Testing
- Cangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor)
- Where
- United States
- Volunteers
- 8,882 people
- Sponsor
- The Medicines Company
Coronary Artery Disease, ST-segment Elevation Myocardial Infarction
Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
The purpose of this study is to prospectively observe the incidence rate of acute kidney injury (AKI), major adverse renal and cardiovascular events (MARCE) in participants who were diagnosed with ST-segment elevation myocardial…
- Trial name
- NCT03671603
- Testing
- Iodixanol
- Where
- 36 sites in China, South Korea
- Volunteers
- 2,755 people
- Sponsor
- GE Healthcare